Chinook Therapeutics (KDNY) News Today → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free KDNY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 21, 2024 | finance.yahoo.comThree Finalists Announced for the 2024 Bloom Burton AwardNovember 1, 2023 | usnews.comChinook ElementarySeptember 12, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) is Altium Capital Management LP's 5th Largest PositionAltium Capital Management LP reduced its holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 20.8% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 305,000 shares of the company's stock afterSeptember 6, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Consensus Recommendation of "Hold" from AnalystsShares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Free Report) have earned an average recommendation of "Hold" from the thirteen research firms that are currently covering the stock, Marketbeat reports. Ten analysts have rated the stock with a hold rating and three have assigned a buy ratingSeptember 4, 2023 | marketbeat.comCitigroup Inc. Boosts Holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY)Citigroup Inc. raised its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 89.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 147,810 shares of the company's stock aftSeptember 1, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by C M Bidwell & Associates Ltd.C M Bidwell & Associates Ltd. lowered its stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 86.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,490 shares of the company's stockAugust 25, 2023 | marketbeat.comCHI Advisors LLC Makes New Investment in Chinook Therapeutics, Inc. (NASDAQ:KDNY)CHI Advisors LLC acquired a new stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 135,000 shares of the company's stock, valued at approximately $3,125,000.August 20, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. decreased its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 27.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 170,211 shares of the cAugust 18, 2023 | marketbeat.comBarclays PLC Lowers Stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY)Barclays PLC cut its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 17.7% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 83,925 shares of the company'sAugust 11, 2023 | marketbeat.comTrading was temporarily halted for "KDNY" at 07:08 PM with a stated reason of "News pending."August 10, 2023 | marketbeat.comQ3 2023 Earnings Forecast for Chinook Therapeutics, Inc. Issued By Wedbush (NASDAQ:KDNY)Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) - Investment analysts at Wedbush upped their Q3 2023 EPS estimates for Chinook Therapeutics in a research report issued to clients and investors on Tuesday, August 8th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.7August 8, 2023 | msn.comWedbush Downgrades Chinook Therapeutics (KDNY)August 2, 2023 | uk.finance.yahoo.comChinook Therapeutics, Inc. (KDNY)August 1, 2023 | markets.businessinsider.comExpert Ratings for Chinook TherapeuticsAugust 1, 2023 | msn.comWells Fargo Downgrades Chinook Therapeutics (KDNY)August 1, 2023 | marketbeat.comChinook Therapeutics (NASDAQ:KDNY) Downgraded by Wells Fargo & Company to Equal WeightWells Fargo & Company downgraded shares of Chinook Therapeutics from an "overweight" rating to an "equal weight" rating in a research note on Tuesday.July 28, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by Baillie Gifford & Co.Baillie Gifford & Co. lowered its stake in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 0.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 486,595 shares of the company's stockJuly 25, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOTJuly 20, 2023 | marketbeat.comSG Americas Securities LLC Increases Position in Chinook Therapeutics, Inc. (NASDAQ:KDNY)SG Americas Securities LLC raised its holdings in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 1,818.5% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 153,882 shares of the company's stock after acquiJuly 18, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Rating of "Hold" from AnalystsChinook Therapeutics, Inc. (NASDAQ:KDNY - Get Free Report) has been assigned an average recommendation of "Hold" from the thirteen brokerages that are covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a hold recommendation and five have assigned a buJuly 16, 2023 | fool.comChinook Therapeutics (NASDAQ: KDNY)July 7, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Position Increased by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. lifted its holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 40.1% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 36,946 shares of the company's stock after buying an additional 10,5June 30, 2023 | marketbeat.comShort Interest in Chinook Therapeutics, Inc. (NASDAQ:KDNY) Drops By 56.4%Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 1,820,000 shares, a drop of 56.4% from the May 31st total of 4,170,000 shares. Based on an average daily volume of 1,330,000 shares, the days-to-cover ratio is currently 1.4 days.June 29, 2023 | marketbeat.comAssenagon Asset Management S.A. Purchases 483,220 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)Assenagon Asset Management S.A. grew its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Free Report) by 54.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,371,469 sJune 23, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Given Average Recommendation of "Hold" by AnalystsChinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) has been given an average recommendation of "Hold" by the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. Eight investment analysts have rated the stock with a hold rating and five have assigned a buy ratingJune 21, 2023 | seekingalpha.comChinook: Surprising Acquisition By Novartis, Deal Should Go ThroughJune 21, 2023 | marketbeat.comVictory Capital Management Inc. Grows Holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY)Victory Capital Management Inc. grew its stake in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 13.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,163,245 shares of the company's stock after acquiring an additional 136,182 shares durinJune 17, 2023 | finance.yahoo.comChinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) CongressJune 16, 2023 | benzinga.comMoore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law FirmJune 15, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Sold by HealthCor Management L.P.HealthCor Management L.P. lowered its holdings in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 77.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,000 shares of the company's stock after sellingJune 14, 2023 | businesswire.comCHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...June 13, 2023 | barrons.comKDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to ShareholdersJune 13, 2023 | marketbeat.comNovartis Stock Screams Value After Chinook Therapeutics Buyout (KDNY)Following a buyout of Chinook Therapeutics, Novartis slipped less than 1%. This speaks to the growth potential of Chinook and ongoing value of Novartis stock.June 13, 2023 | reuters.comNovartis buys Chinook for $3.5 bln in race to treat rare kidney diseaseJune 13, 2023 | markets.businessinsider.comWhy Are Chinook Therapeutics Shares Trading Higher TodayJune 12, 2023 | markets.businessinsider.comWhat 6 Analyst Ratings Have To Say About Chinook TherapeuticsJune 12, 2023 | finance.yahoo.comChinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) CongressJune 12, 2023 | seekingalpha.comNovartis Buys Chinook: M&A To Drive Future GrowthJune 12, 2023 | marketbeat.comChinook Therapeutics (NASDAQ:KDNY) Downgraded to Neutral at GuggenheimGuggenheim cut shares of Chinook Therapeutics from a "buy" rating to a "neutral" rating in a research report on Monday.June 12, 2023 | investorplace.comWhy Is Chinook Therapeutics (KDNY) Stock Up 58% Today?June 9, 2023 | marketbeat.comGyon Technologies Capital Management LP Makes New $496,000 Investment in Chinook Therapeutics, Inc. (NASDAQ:KDNY)Gyon Technologies Capital Management LP acquired a new position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 18,931 shares ofJune 8, 2023 | markets.businessinsider.comChinook Shareholder Action ReminderJune 7, 2023 | marketbeat.comExodusPoint Capital Management LP Sells 41,701 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)ExodusPoint Capital Management LP lowered its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 24.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,955 shares of the company's stock after sellingJune 5, 2023 | marketbeat.comPrincipal Financial Group Inc. Grows Stock Holdings in Chinook Therapeutics, Inc. (NASDAQ:KDNY)Principal Financial Group Inc. lifted its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 102.0% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,555 shares of the company's stock after buJune 2, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Shares Acquired by Mirae Asset Global Investments Co. Ltd.Mirae Asset Global Investments Co. Ltd. grew its position in Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 22.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 24,413 shares of the company's stock after acquiring an additional 4May 29, 2023 | marketbeat.comChinook Therapeutics, Inc. (NASDAQ:KDNY) Given Average Recommendation of "Buy" by BrokeragesChinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) has been given an average rating of "Buy" by the eight analysts that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brMay 26, 2023 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 51,468 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)Connor Clark & Lunn Investment Management Ltd. reduced its position in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 17.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 235,816 shares of tMay 25, 2023 | marketbeat.comSwiss National Bank Acquires 5,200 Shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY)Swiss National Bank lifted its holdings in shares of Chinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) by 5.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 98,700 shares of the comMay 24, 2023 | marketbeat.comFY2023 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Reduced by AnalystChinook Therapeutics, Inc. (NASDAQ:KDNY - Get Rating) - Research analysts at Bloom Burton decreased their FY2023 earnings per share estimates for shares of Chinook Therapeutics in a research note issued on Monday, May 22nd. Bloom Burton analyst A. Borovina now forecasts that the company will earnMay 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS) Get Chinook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter. Email Address This unknown company solves the biggest issue with AI (Ad)Nvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company KDNY Media Mentions By Week KDNY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KDNY News Sentiment▼0.670.55▲Average Medical News Sentiment KDNY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KDNY Articles This Week▼01▲KDNY Articles Average Week Get Chinook Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KDNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: OLK News Today QDEL News Today ENOV News Today MRUS News Today ACAD News Today LTH News Today CERT News Today GDRX News Today TNDM News Today ACLX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KDNY) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chinook Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
